Osborne CK - Search Results

1

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials.

Howell A, Pippen J, Elledge RM, Mauriac L, Vergote I, Jones SE, Come SE, Osborne CK, Robertson JF. Howell A, et al. Among authors: osborne ck. Cancer. 2005 Jul 15;104(2):236-9. doi: 10.1002/cncr.21163. Cancer. 2005. PMID: 15937908 Free article. Clinical Trial.

2

Prognostic factors in breast cancer.

Elledge RM, McGuire WL, Osborne CK. Elledge RM, et al. Among authors: osborne ck. Semin Oncol. 1992 Jun;19(3):244-53. Semin Oncol. 1992. PMID: 1351692 Review. No abstract available.

3

A Southwest Oncology Group phase II Trial of recombinant tumor necrosis factor in metastatic breast cancer.

Budd GT, Green S, Baker LH, Hersh EP, Weick JK, Osborne CK. Budd GT, et al. Among authors: osborne ck. Cancer. 1991 Oct 15;68(8):1694-5. doi: 10.1002/1097-0142(19911015)68:8<1694::aid-cncr2820680806>3.0.co;2-k. Cancer. 1991. PMID: 1913510 Clinical Trial.

4

Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer.

Elledge RM, Gray R, Mansour E, Yu Y, Clark GM, Ravdin P, Osborne CK, Gilchrist K, Davidson NE, Robert N, et al. Elledge RM, et al. Among authors: osborne ck. J Natl Cancer Inst. 1995 Aug 16;87(16):1254-6. doi: 10.1093/jnci/87.16.1254. J Natl Cancer Inst. 1995. PMID: 7563172 Clinical Trial. No abstract available.

5

Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States.

Elledge RM, Clark GM, Chamness GC, Osborne CK. Elledge RM, et al. Among authors: osborne ck. J Natl Cancer Inst. 1994 May 4;86(9):705-12. doi: 10.1093/jnci/86.9.705. J Natl Cancer Inst. 1994. PMID: 7908990

6

Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer.

Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, Osborne CK, McGuire WL. Allred DC, et al. Among authors: osborne ck. J Natl Cancer Inst. 1993 Feb 3;85(3):200-6. doi: 10.1093/jnci/85.3.200. J Natl Cancer Inst. 1993. PMID: 8423624

7

bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study.

Elledge RM, Green S, Howes L, Clark GM, Berardo M, Allred DC, Pugh R, Ciocca D, Ravdin P, O'Sullivan J, Rivkin S, Martino S, Osborne CK. Elledge RM, et al. Among authors: osborne ck. J Clin Oncol. 1997 May;15(5):1916-22. doi: 10.1200/JCO.1997.15.5.1916. J Clin Oncol. 1997. PMID: 9164202

8

Oestrogen receptors and breast cancer.

Elledge RM, Osborne CK. Elledge RM, et al. Among authors: osborne ck. BMJ. 1997 Jun 28;314(7098):1843-4. doi: 10.1136/bmj.314.7098.1843. BMJ. 1997. PMID: 9224112 Free PMC article. No abstract available.

9

Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors.

Johnston SR, Lu B, Dowsett M, Liang X, Kaufmann M, Scott GK, Osborne CK, Benz CC. Johnston SR, et al. Among authors: osborne ck. Cancer Res. 1997 Sep 1;57(17):3723-7. Cancer Res. 1997. PMID: 9288779

10

HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.

Elledge RM, Green S, Ciocca D, Pugh R, Allred DC, Clark GM, Hill J, Ravdin P, O'Sullivan J, Martino S, Osborne CK. Elledge RM, et al. Among authors: osborne ck. Clin Cancer Res. 1998 Jan;4(1):7-12. Clin Cancer Res. 1998. PMID: 9516946

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

377 results

Search Page

Filters